Oncotelic Therapeutics Inc. (OTCQB: OTLC) has launched an AI-powered manufacturing services platform designed to address a critical bottleneck for emerging biotechnology companies: access to full Good Manufacturing Practice (GMP) infrastructure. The platform integrates Oncotelic's proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company's strategic robotics and automation partner.
The initiative extends beyond typical AI applications in drug discovery by embedding artificial intelligence directly into manufacturing workflows. This integration aims to ensure that therapies move efficiently from development toward commercialization. Already deployed at Oncotelic's GMP-certified SAPU manufacturing facility to support its own clinical pipeline, the platform adds a second dimension to the company's business model. While Oncotelic remains a clinical-stage biotech, the AI-GMP platform could position it as an enabling infrastructure provider for other drug developers. If adopted commercially, this creates a services-based revenue opportunity while strengthening Oncotelic's internal development engine.
Combined with TechForce Robotics' automation capabilities, the launch reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline. The platform is expected to help smaller biotech firms overcome the high costs and complexity of establishing GMP-compliant manufacturing, a common hurdle that can delay or derail promising therapies.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, Oncotelic licenses and codevelops select drug candidates through joint ventures, including a 45% ownership stake in GMP Bio, a venture advancing its own pipeline of drug candidates that complement Oncotelic's strategic position in oncology and rare disease therapeutics.
For more information on the platform, view the full article at https://ibn.fm/zB53J. Updates on Oncotelic are available in the company's newsroom at https://ibn.fm/OTLC.
